Effects of Fruquintinib on the Pluripotency Maintenance and Differentiation Potential of Mouse Embryonic Stem Cells

Effects of Fruquintinib on the Pluripotency Maintenance and Differentiation Potential of Mouse Embryonic Stem Cells

Mouse embryonic stem cells (mESCs) can keep self-renewal and differentiate into any cell kind of the three main germ layers. The vascular endothelial progress issue (VEGF) is concerned within the regulation of mESC differentiation and induces the activation of a collection of kinase responses and several other cell signaling pathways by binding to its respective transmembrane receptors, vascular endothelial progress issue receptor VEGFR1, and VEGFR2.
Fruquintinib is a selective inhibitor of VEGFRs, and we used it to research the results on the upkeep of pluripotency and differentiation potential of mESCs on this examine. Our outcomes confirmed that fruquintinib-treated cells expressed greater ranges of pluripotent markers, together with Oct4, Nanog, Sox2, and Esrrb below serum and leukemia inhibitory issue (LIF) situation, whereas the expression of phosphorylated Erk1/2 was restricted.
Mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (MEK) signaling inhibitor (PD0325901) and glycogen synthase kinase 3 (GSK3) signaling inhibitor (CHIR99021) (also referred to as 2i) allow cells to keep up naive pluripotency with LIF, and fruquintinib may promote cells to keep up naive pluripotent state even below serum/LIF situation, whereas VEGF addition limits the pluripotency traits in serum/LIF mESCs.
Moreover, fruquintinib might inhibit the three-germ layer institution in embryoid physique formation and keep the undifferentiated traits of mESCs, indicating that fruquintinib might promote the upkeep of naive pluripotency and inhibit early differentiation packages.

A Gene Expression Signature to Predict Nucleotide Excision Restore Defects and Novel Therapeutic Approaches

Nucleotide excision restore (NER) resolves DNA adducts, equivalent to these attributable to ultraviolet gentle. Poor NER (dNER) ends in the next mutation price that may predispose to most cancers growth and untimely ageing phenotypes.
Right here, we used isogenic dNER mannequin cell traces to determine a gene expression signature that may precisely predict purposeful NER capability in each cell traces and affected person samples. Critically, not one of the recognized NER poor cell traces harbored mutations in any NER genes, suggesting that the prevalence of NER defects might at present be underestimated.
Effects of Fruquintinib on the Pluripotency Maintenance and Differentiation Potential of Mouse Embryonic Stem Cells
Identification of compounds that induce the dNER gene expression signature led to the invention that NER may be functionally impaired by GSK3 inhibition, resulting in synergy when mixed with cisplatin remedy.
Moreover, we predicted and validated a number of novel medicine which are synthetically deadly with NER defects utilizing the dNER gene signature as a drug discovery platform. Taken collectively, our work supplies a dynamic predictor of NER operate that could be utilized for therapeutic stratification in addition to growth of novel organic insights in human tumors.
Effects of Fruquintinib on the Pluripotency Maintenance and Differentiation Potential of Mouse Embryonic Stem Cells

Cell floor integrin α5ß1 clustering negatively regulates receptor tyrosine kinase signaling in colorectal most cancers cells through glycogen synthase kinase 3

As a key course of throughout the tissue microenvironment, integrin signaling can affect cell purposeful responses to progress issue stimuli. We present right here that clustering of integrin α5ß1 on the plasma membrane of colorectal cancer-derived epithelial cells modulates their skill to answer stimulation by receptor tyrosine kinase (RTK)-activating progress elements EGF, NRG and HGF, via GSK3-mediated suppression of Akt pathway.
We noticed that integrin α5ß1 is misplaced from the membrane of poorly organized human colorectal tumors and that remedy with the integrin-clustering antibody P4G11 is enough to induce polarity in a mouse tumor xenograft mannequin.
Whereas including RTK progress elements (EGF, NRG and HGF) to polarized colorectal most cancers cells induced invasion and lack of monolayer formation in 2D and 3D, this pathological conduct might be blocked by P4G11. Phosphorylation of ErbB members of the family in addition to MET following EGF, NRG and HGF remedy was diminished in cells pretreated with P4G11.
Specializing in EGFR, we discovered that blockade of integrin α5ß1 elevated EGFR phosphorylation. Since exercise of a number of downstream kinase pathways have been altered by these numerous therapies, we employed computational machine studying strategies to establish crucial results. Partial least-squares discriminant evaluation recognized GSK3 as a serious regulator of EGFR pathway actions influenced by integrin α5ß1.
Furthermore, we used partial correlation evaluation to look at signaling pathway crosstalk downstream of EGF stimulation and located that integrin α5ß1 acts as a destructive regulator of the AKT signaling cascade downstream of EGFR, with GSK3 appearing as a key mediator. We experimentally validated these computational inferences by confirming that blockade of GSK3 exercise is enough to induce lack of polarity and enhance of oncogenic signaling within the colonic epithelial cells.

Hawthorn polyphenols, D-chiro-inositol, and epigallocatechin gallate exert a synergistic hypoglycemic impact

Hawthorn berry has been proved hypoglycemic impact as a result of presence of some α-glucosidase inhibitors. Herein, screening and figuring out of α-glucosidase inhibitors from hawthorn berry have been performed, and the outcomes confirmed polyphenols primarily containing quercetin (74.58%) and hyperioside (9.58%) have been chargeable for its bioactivity.
With a purpose to improve the hypoglycemic impact, the mixed glucose-lowering advanced (DEH) consisting of hawthorn polyphenols, D-chiro-inositol (DCI), and epigallocatechin gallate (EGCG) was ready, the place three elements exerted the synergistic hypoglycemic impact to boost glucose consumption and glycogen ranges and inhibit hepatic gluconeogenesis in IR-HepG2 cells.
In STZ/HFD-induced mice, DEH successfully improved insulin resistance, lowered fasting blood glucose (FBG) and hepatic gluconeogenesis, and elevated hepatic glycogen synthesis and storage through down-regulation of PI3K/Akt/FOXO1-mediated PEPCK and G6Pase and up-regulation of PI3K/Akt/GSK3-mediated GS activation within the liver. In abstract, these findings point out that DEH is a possible novel technique for the remedy of kind 2 diabetes.
PRACTICAL APPLICATIONS: Glucose-lowering advanced (DEH) with superior hypoglycemic impact, can successfully enhance the insulin resistance, cut back the fasting blood glucose, hepatic gluconeogenesis and enhance the hepatic glycogen synthesis and storage in mice, which represents a possible novel technique for the remedy of kind 2 diabetes.

Isoorientin inhibits epithelial-to-mesenchymal properties and most cancers stem-cell-like options in oral squamous cell carcinoma by blocking Wnt/β-catenin/STAT3 axis

Oral squamous cell carcinoma (OSCC) is among the many most prevalent cancers of the top and neck. This examine revealed that isoorientin attenuates OSCC cell stemness and epithelial-mesenchymal transition potential via the inhibition of JAK/sign transducer and activator of transcription 3 (STAT3) and Wnt/β-catenin signaling in cell traces. Our findings indicated that isoorientin is a possible inhibitor of β-catenin/STAT3 in vitro and in vivo.
We analyzed doable synergism between isoorientin and cisplatin in OSCC. A sulforhodamine B assay, colony formation assay, tumorsphere-formation assay, and Wnt reporter exercise assay have been used for figuring out cell invasion, cell migration, drug cytotoxicity, and cell viability with potential molecular mechanisms in vitro. Isoorientin lowered the expression of p-STAT3, β-catenin, and p-GSK3 in addition to downstream effectors TCF1/TCF7 and LEF1 and considerably lowered β-catenin colocalization within the nucleus.
Isoorientin markedly strengthened the cytotoxic results of cisplatin towards SAS and SCC-25. Due to this fact, combining isoorientin and cisplatin therapies can probably enhance the anticancer impact of cisplatin. Isoorientin inhibited the tumorigenicity and progress of OSCC via the abrogation of Wnt/β-catenin/STAT3 signaling in vivo.

GSK3 alpha antibody

70R-34164 100 ug
EUR 392.4
Description: Rabbit polyclonal GSK3 alpha antibody

GSK3 alpha Antibody

48179-100ul 100ul
EUR 399.6

GSK3 alpha Antibody

48179-50ul 50ul
EUR 286.8

GSK3 alpha antibody

20R-1883 50 ug
EUR 337.2
Description: Rabbit polyclonal GSK3 alpha antibody

GSK3 alpha antibody

20R-2192 50 ug
EUR 337.2
Description: Rabbit polyclonal GSK3 alpha antibody

GSK3 alpha antibody

10R-1930 100 ul
EUR 483.6
Description: Mouse monoclonal GSK3 alpha antibody

GSK3 alpha antibody

10R-2025 100 ul
EUR 522
Description: Mouse monoclonal GSK3 alpha antibody

GSK3 alpha antibody

10R-2104 100 ul
EUR 483.6
Description: Mouse monoclonal GSK3 alpha antibody

GSK3 alpha Antibody

20-abx133173
  • EUR 360.00
  • EUR 526.80
  • EUR 226.80
  • 100 ul
  • 200 ul
  • 30 ul

GSK3 alpha Antibody

abx015750-100ul 100 ul
EUR 493.2

GSK3 alpha Antibody

abx015751-100ul 100 ul
EUR 493.2

GSK3 alpha Antibody

abx010857-100ul 100 ul
EUR 493.2

GSK3 alpha Antibody

20-abx012858
  • EUR 376.80
  • EUR 117.60
  • EUR 477.60
  • EUR 594.00
  • 100 ug
  • 10 ug
  • 200 ug
  • 300 µg

GSK3 alpha Antibody

abx033883-400ul 400 ul
EUR 627.6

GSK3 alpha Antibody

abx033883-80l 80 µl
EUR 343.2

GSK3 alpha Antibody

ABF6336 100 ug
EUR 525.6

GSK3 alpha Antibody

BF0391 200ul
EUR 540

GSK3 alpha/ beta Antibody

DF6806 200ul
EUR 420

GSK3 alpha/ beta Antibody

AF6335 200ul
EUR 420

GSK3 alpha Conjugated Antibody

C48179 100ul
EUR 476.4

GSK3 alpha/beta antibody

70R-49831 100 ul
EUR 292.8
Description: Purified Polyclonal GSK3 alpha/beta antibody

GSK3 alpha antibody (Ser21)

70R-34163 100 ug
EUR 392.4
Description: Rabbit polyclonal GSK3 alpha antibody (Ser21)

GSK3 alpha antibody (Ser21)

70R-37089 100 ug
EUR 418.8
Description: Rabbit Polyclonal GSK3 alpha antibody (Ser21)

GSK3 alpha/beta antibody

70R-51552 100 ul
EUR 344.4
Description: Purified Polyclonal GSK3 alpha/beta antibody

GSK3 alpha/beta antibody

70R-30578 100 ug
EUR 392.4
Description: Rabbit polyclonal GSK3 alpha/beta antibody

GSK3 alpha/beta Antibody

29039-100ul 100ul
EUR 302.4

GSK3 alpha (pS21) Antibody

abx010870-100ug 100 ug
EUR 526.8

GSK3 alpha / beta Antibody

20-abx009185
  • EUR 360.00
  • EUR 526.80
  • EUR 226.80
  • 100 ul
  • 200 ul
  • 30 ul

GSK3 alpha (pS21) Antibody

20-abx009689
  • EUR 376.80
  • EUR 560.40
  • EUR 243.60
  • 100 ul
  • 200 ul
  • 30 ul

GSK3 alpha/beta Antibody

ABF6335 100 ug
EUR 525.6

GSK3 alpha Antibody / GSK3A

RQ4122 100 ug
EUR 419

GSK3 alpha Antibody / GSK3A

RQ5950 100 ug
EUR 419
Description: Glycogen synthase kinase-3 alpha is an enzyme that in humans is encoded by the GSK3A gene. It is mapped to 19q13.2. This gene encodes a multifunctional Ser/Thr protein kinase that is implicated in the control of several regulatory proteins including glycogen synthase, and transcription factors, such as JUN. It also plays a role in the WNT and PI3K signaling pathways, as well as regulates the production of beta-amyloid peptides associated with Alzheimer's disease.

Rabbit Polyclonal antibody Anti-CRBN

Anti-CRBN 50 µg
EUR 418.8

GSK3 alpha recombinant monoclonal antibody

A5830 100ul X 3
EUR 714
Description: A recombinant monoclonal antibody from rabbit against human GSK3 alpha for WB, IHC,ELISA

Phospho-GSK3 alpha (Ser21) Antibody

AF3336 200ul
EUR 420

Phospho-GSK3 alpha (Ser282) Antibody

AF7313 200ul
EUR 540

GSK3 alpha/beta Conjugated Antibody

C29039 100ul
EUR 476.4

GSK3 alpha (Phospho-Ser282) Antibody

13162-100ul 100ul
EUR 302.4

GSK3 alpha (Phospho-Ser282) Antibody

13162-50ul 50ul
EUR 224.4

GSK3 alpha (Phospho-Ser21) Antibody

20-abx012539
  • EUR 376.80
  • EUR 117.60
  • EUR 477.60
  • EUR 594.00
  • 100 ug
  • 10 ug
  • 200 ug
  • 300 µg

Phospho- GSK3 alpha (Ser21) Antibody

ABF3336 100 ug
EUR 525.6

GSK3 alpha Blocking Peptide

AF7813-BP 1mg
EUR 234

GSK3 alpha Blocking Peptide

AF6336-BP 1mg
EUR 234

GSK3 alpha Blocking Peptide

20-abx161877
  • EUR 326.40
  • EUR 493.20
  • 1 mg
  • 5 mg

GSK3 alpha Blocking Peptide

BF0391-BP 1mg
EUR 234

Anti-GSK3 beta antibody

STJ99095 200 µl
EUR 236.4
Description: Mouse monoclonal to GSK3 beta.

anti-GSK3 beta

YF-PA23834 50 ul
EUR 400.8
Description: Mouse polyclonal to GSK3 beta

anti-GSK3 beta

YF-PA12137 100 ug
EUR 483.6
Description: Rabbit polyclonal to GSK3 beta

GSK3 alpha (Phospho-Ser282) Conjugated Antibody

C13162 100ul
EUR 476.4

GSK3 alpha/beta antibody (Tyr279/216)

70R-30577 100 ug
EUR 392.4
Description: Rabbit polyclonal GSK3 alpha/beta antibody (Tyr279/216)

GSK3 alpha / beta (pY279 / 216) Antibody

20-abx119370
  • EUR 376.80
  • EUR 117.60
  • EUR 477.60
  • EUR 594.00
  • 100 ug
  • 10 ug
  • 200 ug
  • 300 µg

GSK3 alpha / beta (pY279 / 216) Antibody

abx010868-100ug 100 ug
EUR 526.8

GSK3 alpha / beta (pT279 / 216) Antibody

20-abx009652
  • EUR 376.80
  • EUR 560.40
  • EUR 243.60
  • 100 ul
  • 200 ul
  • 30 ul

Monoclonal GSK3 alpha Antibody, Clone: 9D5G1

APR12317G 0.1ml
EUR 580.8
Description: A Monoclonal antibody against Human GSK3 alpha. The antibodies are raised in Mouse and are from clone 9D5G1. This antibody is applicable in WB, ICC, E

Monoclonal GSK3 alpha Antibody, Clone: EP793Y

AMM05996G 0.1ml
EUR 633.6
Description: A Monoclonal antibody against Human GSK3 alpha. The antibodies are raised in Rabbit and are from clone EP793Y. This antibody is applicable in WB and IHC

GSK3 antibody

20R-1609 100 ug
EUR 807.6
Description: Rabbit polyclonal GSK3 antibody

GSK3 Antibody

R34119-100UG 100 ug
EUR 399

GSK3 alpha/beta Blocking Peptide

AF6335-BP 1mg
EUR 234

GSK3 alpha (pS21) Blocking Peptide

20-abx062705
  • EUR 376.80
  • EUR 610.80
  • 1 mg
  • 5 mg

GSK3 alpha / beta Blocking Peptide

20-abx062706
  • EUR 326.40
  • EUR 493.20
  • 1 mg
  • 5 mg

GSK3 alpha protein (GST Fusion)

80R-2554 100 ug
EUR 296.4
Description: Purified recombinant Human GSK3 alpha-GST Fusion protein

Anti-Phospho-GSK3 (alpha + beta) (Y216 + Y279) Rabbit Monoclonal Antibody

P03152-1 100ug/vial
EUR 476.4
Description: Rabbit Monoclonal Phospho-GSK3 (alpha + beta) (Y216 + Y279) Antibody. Validated in IP, IF, WB and tested in Human, Mouse, Rat.

Phospho-GSK3 alpha/ beta (Tyr216/Tyr279) Antibody

AF3335 200ul
EUR 420

GSK3(alpha+beta)(Phospho-Y216+Y279) Antibody

13355-100ul 100ul
EUR 399.6

GSK3(alpha+beta)(Phospho-Y216+Y279) Antibody

13355-50ul 50ul
EUR 286.8

Phospho- GSK3 alpha/ beta (Tyr279/216) Antibody

ABF3335 100 ug
EUR 525.6

Polyclonal GSK3 alpha (GSK3A) Antibody (N-term)

APR12316G 0.1ml
EUR 580.8
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human GSK3 alpha (GSK3A) (N-term). This antibody is tested and proven to work in the following applications:

Monoclonal GSK3 alpha/beta Antibody, Clone: EP933Y

APR12318G 0.1ml
EUR 633.6
Description: A Monoclonal antibody against Human GSK3 alpha/beta. The antibodies are raised in Rabbit and are from clone EP933Y. This antibody is applicable in WB

Monoclonal GSK3 alpha Antibody, Clone: 6G2F1; 6G2F2

AMM02621G 0.1ml
EUR 633.6
Description: A Monoclonal antibody against Human GSK3 alpha. The antibodies are raised in Mouse and are from clone 6G2F1; 6G2F2. This antibody is applicable in WB and IHC, E

Polyclonal GSK3 alpha (GSK3A) Antibody (C-term)

APS00025G 0.1ml
EUR 580.8
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human GSK3 alpha (GSK3A) (C-term). This antibody is tested and proven to work in the following applications:

anti-GSK3 β (AF12E8)

LF-MA0315 100 ul
EUR 400.8
Description: Mouse monoclonal to GSK3 β

Anti-GSK3 beta (1H3)

YF-MA10388 100 ug
EUR 435.6
Description: Mouse monoclonal to GSK3 beta

GSK3

EF016956 96 Tests
EUR 826.8

Gsk3

EF012988 96 Tests
EUR 826.8

GSK3

EF014015 96 Tests
EUR 826.8

GSK3

EF006886 96 Tests
EUR 826.8

GSK3

EF000406 96 Tests
EUR 826.8

Phospho-GSK3 alpha (Ser21) Blocking Peptide

AF3336-BP 1mg
EUR 234

Phospho-GSK3 alpha (Ser282) Blocking Peptide

AF7313-BP 1mg
EUR 234

[KO Validated] GSK3 alpha Rabbit mAb

A19060-100ul 100 ul
EUR 492

[KO Validated] GSK3 alpha Rabbit mAb

A19060-200ul 200 ul
EUR 685.2

[KO Validated] GSK3 alpha Rabbit mAb

A19060-20ul 20 ul
EUR 265.2

[KO Validated] GSK3 alpha Rabbit mAb

A19060-50ul 50 ul
EUR 344.4

Anti-GSK3 beta Rabbit Monoclonal Antibody

M00791 100ug/vial
EUR 476.4
Description: Rabbit Monoclonal GSK3 beta Antibody. Validated in IF, IHC, WB and tested in Human, Mouse, Rat.

GSK3 beta Antibody

DF7231 200ul
EUR 420

GSK3 beta Antibody

AF7814 200ul
EUR 540

GSK3 beta Antibody

AF5016 200ul
EUR 420

GSK3 beta Antibody

AF6658 100ul
EUR 420

GSK3? Polyclonal Antibody

ES2485-100ul 100ul
EUR 334.8
Description: A Rabbit Polyclonal antibody against GSK3? from Human/Mouse/Rat. This antibody is tested and validated for WB, ELISA, IHC, IP, WB, ELISA

GSK3? Polyclonal Antibody

ES2485-50ul 50ul
EUR 248.4
Description: A Rabbit Polyclonal antibody against GSK3? from Human/Mouse/Rat. This antibody is tested and validated for WB, ELISA, IHC, IP, WB, ELISA

GSK3?/? Polyclonal Antibody

ES2486-100ul 100ul
EUR 334.8
Description: A Rabbit Polyclonal antibody against GSK3?/? from Human/Mouse/Rat. This antibody is tested and validated for WB, ELISA, IHC, WB, ELISA

GSK3?/? Polyclonal Antibody

ES2486-50ul 50ul
EUR 248.4
Description: A Rabbit Polyclonal antibody against GSK3?/? from Human/Mouse/Rat. This antibody is tested and validated for WB, ELISA, IHC, WB, ELISA

GSK3? Polyclonal Antibody

ES2487-100ul 100ul
EUR 334.8
Description: A Rabbit Polyclonal antibody against GSK3? from Human/Mouse/Rat. This antibody is tested and validated for WB, ELISA, IHC, IP, WB, ELISA

GSK3? Polyclonal Antibody

ES2487-50ul 50ul
EUR 248.4
Description: A Rabbit Polyclonal antibody against GSK3? from Human/Mouse/Rat. This antibody is tested and validated for WB, ELISA, IHC, IP, WB, ELISA

GSK3? Polyclonal Antibody

ES8198-100ul 100ul
EUR 334.8
Description: A Rabbit Polyclonal antibody against GSK3? from Mouse/Rat. This antibody is tested and validated for WB, ELISA, IHC

GSK3? Polyclonal Antibody

ES8198-50ul 50ul
EUR 248.4
Description: A Rabbit Polyclonal antibody against GSK3? from Mouse/Rat. This antibody is tested and validated for WB, ELISA, IHC

GSK3? Polyclonal Antibody

ES5683-100ul 100ul
EUR 334.8
Description: A Rabbit Polyclonal antibody against GSK3? from Human/Mouse/Rat. This antibody is tested and validated for WB, ELISA, IHC, WB, ELISA

GSK3? Polyclonal Antibody

ES5683-50ul 50ul
EUR 248.4
Description: A Rabbit Polyclonal antibody against GSK3? from Human/Mouse/Rat. This antibody is tested and validated for WB, ELISA, IHC, WB, ELISA

GSK3 beta antibody

70R-37442 100 ug
EUR 327.6
Description: Rabbit Polyclonal GSK3 beta antibody

GSK3 beta antibody

70R-49832 100 ul
EUR 344.4
Description: Purified Polyclonal GSK3 beta antibody

GSK3 beta antibody

70R-34165 100 ug
EUR 392.4
Description: Rabbit polyclonal GSK3 beta antibody

GSK3 beta antibody

70R-34639 100 ug
EUR 392.4
Description: Purified Rabbit polyclonal GSK3 beta antibody

GSK3 beta antibody

70R-30634 100 ug
EUR 392.4
Description: Rabbit polyclonal GSK3 beta antibody

GSK3 beta Antibody

48798-100ul 100ul
EUR 399.6

GSK3 beta Antibody

48798-50ul 50ul
EUR 286.8

GSK3 beta antibody

20R-1878 50 ug
EUR 337.2
Description: Rabbit polyclonal GSK3 beta antibody

GSK3 beta antibody

20R-2124 50 ug
EUR 337.2
Description: Rabbit polyclonal GSK3 beta antibody

GSK3 beta antibody

20R-2187 50 ug
EUR 337.2
Description: Rabbit polyclonal GSK3 beta antibody

GSK3 beta antibody

20R-2452 50 ug
EUR 337.2
Description: Rabbit polyclonal GSK3 beta antibody

GSK3 beta antibody

10R-8595 100 ul
EUR 471.6
Description: Mouse monoclonal GSK3 beta antibody

GSK3 (pS9) Antibody

20-abx000124
  • EUR 594.00
  • EUR 844.80
  • EUR 260.40
  • EUR 427.20
  • 100 ul
  • 200 ul
  • 20 ul
  • 50 ul

GSK3 beta Antibody

ABF5016 100 ug
EUR 525.6

GSK3 beta Antibody

abx449182-100ug 100 ug
EUR 661.2

GSK3 beta antibody

BF0721 200ul
EUR 540

GSK3(alpha+beta)(Phospho-Y216+Y279) Conjugated Antibody

C13355 100ul
EUR 476.4

anti-GSK3 Beta IgG2a mAb

011-A-01mg 0,1 mg
EUR 321
Description: anti-GSK3 Beta IgG2a (monoclonal). Produced against a recombinant Xenopus laevis protein.

anti-GSK3 Beta IgG2a mAb

011-A-1000ug 1000 ug
EUR 1539
Description: anti-GSK3 Beta IgG2a (monoclonal). Produced against a recombinant Xenopus laevis protein.

GSK3 alpha / beta (pY279 / 216) Blocking Peptide

20-abx062127
  • EUR 376.80
  • EUR 610.80
  • 1 mg
  • 5 mg

Rabbit Anti Gsk3 Beta (Pser9) Polyclonal Antibody

CPBT-66459RG 0.1 ml
EUR 1182

Phospho-GSK3 (alpha+beta)(Y216+Y279) recombinant monoclonal antibody

A5960 100ul X 3
EUR 817.2
Description: A recombinant monoclonal antibody from rabbit against human Phospho-GSK3 (alpha+beta)(Y216+Y279) for WB,ELISA

GSK3 beta Conjugated Antibody

C48798 100ul
EUR 476.4

GSK3? (2C6) Monoclonal Antibody

EM1283-100ul 100ul
EUR 334.8
Description: A Mouse Monoclonal antibody against GSK3? (2C6) from Human/ Rat/ Mouse. This antibody is tested and validated for WB, ELISA, IHC

GSK3? (2C6) Monoclonal Antibody

EM1283-50ul 50ul
EUR 248.4
Description: A Mouse Monoclonal antibody against GSK3? (2C6) from Human/ Rat/ Mouse. This antibody is tested and validated for WB, ELISA, IHC

GSK3 beta antibody (Tyr216)

70R-37352 100 ug
EUR 418.8
Description: Rabbit Polyclonal GSK3 beta antibody (Tyr216)

GSK3 beta antibody (Ser9)

70R-37084 100 ug
EUR 418.8
Description: Rabbit Polyclonal GSK3 beta antibody (Ser9)

GSK3 beta antibody (Ser9)

70R-30633 100 ug
EUR 392.4
Description: Rabbit polyclonal GSK3 beta antibody (Ser9)

GSK3 beta (pS9) Antibody

20-abx133097
  • EUR 376.80
  • EUR 560.40
  • EUR 243.60
  • 100 ul
  • 200 ul
  • 30 ul

GSK3 beta (pS9) Antibody

20-abx119160
  • EUR 376.80
  • EUR 117.60
  • EUR 477.60
  • EUR 594.00
  • 100 ug
  • 10 ug
  • 200 ug
  • 300 µg

GSK3 beta (pS9) Antibody

20-abx119162
  • EUR 376.80
  • EUR 117.60
  • EUR 477.60
  • EUR 594.00
  • 100 ug
  • 10 ug
  • 200 ug
  • 300 µg
Thus, isoorientin disrupted the β-catenin signaling pathway via the inactivation of STAT3 signaling. In conclusion, focusing on OSCC-SC-mediated stemness with isoorientin to eradicate OSCC-SCs could also be an efficient technique for stopping relapse and metastasis of OSCC and offering long-term survival advantages.

Leave a Reply

Your email address will not be published. Required fields are marked *